INTRODUCTION
Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that falls in between the indolent and aggressive subtypes of non-Hodgkin's lymphoma (NHL). MCL combines the incurable feature of indolent lymphomas with the clinical course of aggressive lymphomas. According to the Saudi Cancer Registry, in 2015, NHL was the second and fifth most common cancer among Saudi male and female population, respectively, accounting for 6.9% of all cancers. [1] However, the incidence of MCL in Saudi Arabia is yet unknown, whereas in the United States and Europe, MCL constitutes about 7% of adult NHLs. [2, 3] In MCL, extranodal involvement is common, including bone marrow and peripheral blood. It also has a peculiar tendency to involve the gastrointestinal (GI) tract. Subclinical GI epithelial invasion without overt colonic polyposis is very common. Therefore, a high index of suspicion is required for detecting GI involvement in MCL patients, especially among those presenting with iron deficiency anemia. 
METHODS
A committee comprising experts in hematology and medical oncology was established under the supervision of the Saudi Lymphoma Group and in collaboration with the Saudi Oncology Society. For collecting evidence, a literature search was carried out with relevant keywords using online database search engines such as PubMed/Medline, Web of Science and Scopus. In addition, expert opinion was considered when necessary. The levels of evidence used in developing this guideline were as follows: This easy-to-follow grading system is convenient for readers to understand and allows an accurate assessment of the guideline's applicability in individual patients. [5] 1. PATHOLOGIC DIAGNOSIS 1.1.4. Cyclin D1 expression is a hallmark of MCL. In cyclin D1-negative cases, SOX11 can be useful in the diagnosis (EL-3) [7] 1.1.5. In terms of immunophenotype, MCL cells are typically positive for CD5, FMC7, bright CD20 and CD43, but negative for CD10 and CD23 (EL-3) [8] 1.1.6. In terms of genetic variance, although not specific for MCL and found in other indolent NHLs, almost all MCL cases harbor the cyclin D1 translocation t(11;14) (q13;q32), which can be detected by fluorescence in situ hybridization or the traditional karyotypic analysis (EL-3). [9] 2. DIAGNOSIS AND WORKUP 2. and require treatment. However, few patients have a course similar to that of indolent lymphomas, and in these cases, a period of observation is recommended (EL-3) [13] 3.3.3. In MCL patients aged ≤60 years, dose-intensified therapies (e.g. autologous stem cell transplant-based regimens) should be considered. [14] [15] [16] 3.3.6. Induction therapy 3.3.6.1. Aggressive regimens: 3.3.6.1.1 The preferred regimen for advanced stages is alternating RCHOP/RDHAP (rituximab plus dexamethasone, high-dose cytarabine, and cisplatin) followed by myeloablative autologous stem cell transplant in patients achieving at least a partial response (≥75%) [17, 18] 3.3.6.1.2. A n o t h e r o p t i o n i s cyclophosphamide, vincristine, doxorubicin and dexamethasone (HyperCVAD) alternated with high-dose methotrexate and cytarabine plus rituximab (EL-2) [19, 20] 3.3.6.1.3. For maintenance after autologous stem cell transplant, rituximab should be given every 8 weeks for 3 years (EL-1). [21] 3.3.6.2. Less aggressive therapies for elderly or unfit patients: 3.3.6.2.1. Combination of bendamustine and rituximab (EL-1) [22, 23] 3.3.6.2.1. RCHOP followed by maintenance rituximab every 8 weeks until progression or intolerance (EL-1) [24] 3.3.6.2.1. B o r t e z o m i b, r i t u x i m a b, cyclophosphamide, doxorubicin and prednisone (VR-CAP) (EL-1) [25] 3.3.6.2.1. Combination of lenalidomide and rituximab (EL-2). [26] 3.3.6.3. Therapy for relapsed/refractory disease (second-line therapy): 3.3.6.3.1. Ibrutinib in combination or without rituximab (EL-1) [27] [28] [29] [30] 3.3.6.3.2. Combination of lenalidomide and rituximab (EL-2) [30, 31] 3.3.6.3.3. Other preferred regimens are Venetoclax [32] and Acalabrutinib (EL-2). [33] 3.3.6.4. Consolidation after second-line therapy: 3.3.6.4.1 Allogeneic hematopoietic stem cell transplantation should be considered after achieving c o m p l e t e r e s p o n s e w i t h second-line therapy, if the patient is eligible for transplant (EL-3) [34] 3.3.6.4.2. Autologous transplant could be considered in relapsed patients if not performed as part of the initial treatment (EL-3). [14] 4. FOLLOW UP 4.1. Every 3 months for 2 years, and every 6 months thereafter 4.2. History and physical examination should be documented in every visit 4.3. CBC with differential count and LDH evaluations should be requested in every visit 4.4. CT of neck and CAP is required 3 months after completion of all therapy, and if the findings are normal, no further routine imaging is required 4.5. Annual influenza immunization is recommended (EL-3). [35] Financial support and sponsorship
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